CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for RVL Pharmaceuticals PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

RVL Pharmaceuticals PLC
400 CROSSING BOULEVARD
Phone: (908) 809-1300p:908 809-1300 BRIDGEWATER, NJ  08807  United States Ticker: RVLPQRVLPQ

Business Summary
RVL Pharmaceuticals plc is a pharmaceutical company focused on developing and commercializing eye care and medical aesthetics products. The Company is focused on developing and commercializing products for an underserved patient population in ocular medicine and medical aesthetics. It operates in one business segment which focuses on developing and commercializing pharmaceutical products. The Company is commercializing Upneeq for treating acquired blepharoptosis (low-lying eyelids) in adults and is developing Arbaclofen ER tablets for alleviating spasticity in multiple sclerosis patients. Their healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and other qualified practitioners. The target patient population comprises adults with droopy or low-lying eyelids, primarily females. Its commercial operations are managed by wholly owned subsidiaries, RVL Pharmaceuticals, Inc., and RVL Pharmacy, LLC.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202312/31/2022YesYesYes-Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer, Chief Financial Officer Brian A.Markison 63 4/15/2022 1/1/2016
Chief Operating Officer, Executive Vice President JamesSchaub 41 1/1/2016 1/1/2016
General Counsel, Secretary ChristopherKlein 59 12/1/2013 12/1/2013
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
RevitaLid Pharmaceutical Corp. 400 Crossing Boulevard Bridgewater NJ United States

Business Names
Business Name
Osmotica Argentina, S.A.
Osmotica Kereskedelmi es Szolgaltato Kft
Osmotica Pharmaceutical Corp.
7 additional Business Names available in full report.

General Information
Number of Employees: 125 (As of 12/31/2022)
Outstanding Shares: 111,406,043 (As of 8/30/2023)
Shareholders: 3
Stock Exchange: OTC


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025